

Dextramer[®] technology supporting the development of more potent and effective cell-based therapies

Valérie Bodemeyer, PhD, Technical Application Manager, Immudex Mohammad Salem, PhD, Senior Pharma Business & Solution Manager, Immudex



About us


- Reagents and Kits for antigen-specific cellular immune monitoring
- Services improving immune monitoring
 - Custom Solutions and Services
 - Coming soon Peptide-Binding Evaluation
- Tools for exploring cellular immunity within:
 - Immuno-Oncology
 - Infectious Disease
 - Transplantation
 - Cellular Therapy
 - Autoimmunity
- From Basic research to Diagnostics
 - IVD Kit approved in EU + US
 - Clinical Grade (GMP) reagents

- Based in Copenhagen, Denmark
- North American operations based in Virginia, US




Enabling Characterization of Antigen-Specific Immune Cells


IMMUDEX®





Principles of MHC-Peptide and TCR Interaction








Advancement of MHC Multimer-Based Technologies

Advances in the MHC multimer field improve the detection of antigen-specific T cells:


- Higher-order multimers provide increased avidity in detection of antigen-specific T cells
- Higher-order dextran-based multimers enable detection of low-affinity T cells
- Increased number of fluorophores provides higher resolution when detecting T cells by flow cytometry
- DNA-barcoded multimers and NGS sequencing enhance multiplexing capabilities
- Single-cell multi-omics enables simultaneous acquisition of gene expression, phenotyping and antigen-specificity information



MHC Dextramer[®] Technology – Reliable Detection of Antigen-Specific T-Cells by Flow Cytometry

Features of MHC Dextramer®


- Flexible dextran backbone provides stabilization of MHC Monomers
- Optimized number of MHC Monomers on dextran backbone enhances avidity
- High number of fluorophores provides enhanced resolution and minimal background staining
- High quality and consistency ensured by Immudex's quality control process



High number of Fluorophore (FITC/PE/APC) or None



Monitoring SARS-CoV-2-specific CD8+ T cell responses over time




See full study here

immudex°


Enabling Characterization of Antigen-Specific Immune Cells

IMMUDEX®





Klickmer® Technology




Customize your multimer

A variety of **biotinylated molecules** can be attached to the Klickmer[™] enabling highly sensitive detection of antigen-specific immune cells.


Examples of molecules that can be bound, include:

IMMUDEX

- B-cell antigens
- TCRs
- Peptides
- Interleukins
- Immune stimulatory molecules
- Metal chelates/Lanthanides
- .. And much more!



Applications in CAR-T Cell Therapy



Direct CAR-T cell detection

Enhanced sensitivity for low-affinity CAR-Ts, due to the high avidity of Dextramer[®] technology and multiple fluorophores

Assessment of transduction levels

Determine the % of CAR-T-positive cells

Demonstrate that the infusion product meets defined lot release criteria

Monitor kinetics and persistence of infused CAR-T cells in patient blood samples

Deeper characterization of target-specific CAR-T cells with gene and surface marker expression by single-cell multi-omics

Example 2 – Detecting HLA-A2-specific CAR-Tregs


STUDY DESCRIPTION

Goal: to examine the impact of IL-10 co-expression in engineered HLA-A2-specific CAR-Tregs.

Different CAR-Tregs were generated by lentiviral transduction of 4 different constructs: CAR specific to HLA-A2 alone (A2-CAR), IL-10 alone (IL10-poly), both constructs (IL10-A2-CAR), and neither construct (Poly). The transduction efficiencies were assessed by NIS-TRFP expression by FACS. Transduced cells were further expanded and assessed for phenotype and suppressive function. To quantify the CAR expression, Tregs were stained with MHC I Dextramer[®] reagent specific for HLA-A2 /CINGVCWTV using flow cytometry, whereas IL-10 expression level was assessed by ELISA.

Fig.1.

- A. HLA-A2/CINGVCWTV and HLAB7/APRGVRMAV (control) MHC I Dextramer® reagent were used to quantify CAR surface expression by flow cytometry.
- B. Antigen-specific Treg activation was assessed by CD69 upregulation. Transduced Tregs were cultured with indicated B-LCLs for 18h followed by staining with anti-CD69 antibody and analysis by flow cytometry.



IMMUDEX[®]



dCODE Dextramer[®] Technology – Unravelling the complexity of immune response through single-cell multiomics





dCODE Dextramer[®] Technology From Flow Cytometry to Single Cell Multiomics



- Unique DNA barcodes for each dCODE Dextramer[®]
- Tens to hundreds different dCODE Dextramer[®] used simultaneously
- PE fluorochrome for enrichment of low-frequency cells
- Can be combined with single-cell technologies (BD and 10x Genomics)


dCODE Dextramer[®] 10x and BD Workflows






Enabling Characterization of Antigen-Specific Immune Cells

IMMUDEX®






Detecting Antigen-Specific T Cells









MHC Dextramer®






TCR Dextramer®






The Making of TCRs





TCR DiVa – TCR Discovery & Validation A complete workflow







Artificial Antigen-Presenting Scaffolds: A Tailored Approach for T-Cell Stimulation and Expansion



PAX – New technology for evaluation of

- Potency-Activation-eXpansion

AIM:

Develop robust reagent for stimulation and activation of specific T cells providing a technology:


- Cell-free
- Simple
- Customized
- Standardized

To be used to:

- Evaluate antigen-specific activation of T cells
- Expand antigen-specific T cells
- Explore effect of engineered co-stimulatory signals

Development Outline

- Construct artifical antigen-presenting scaffold (PAX reagent) able to stimulate antigen-specific T cells, providing:
 - Signal 1 TCR-MHCp interaction
 - Signal 2 CD28 engagement




MHCp/aCD28 PAX reagents can activate virus-specific T cells

- inducing cytokine secretion

Evaluate induction of cytokine secretion


- CMV+ PBMC sample comprising T cell subsets specific for:
 - HLA-B*0702/TPRVTGGGAM (MHC_{CMV1})
 - HLA-B*0702/RPHERNGFTVL (MHC_{CMV2})
- Stimulate PBMC with:
 - MHC_{CMV1}/aCD28 PAX
 - MHC_{CMV1} PAX
 - No stimulation
- Assay evaluate IFNγ production (Flow cytometry, ICS)
- Conclusion:
 - PAX reagent displaying MHCp + aCD28 can stimulate antigen-specific T cells to produce IFNγ
 - Highly antigen-specific
 - CD28 engagement improve activation

Stimulated CMV-specific T cells produce IFNy






Antigen-specific expansion of T cells with PAX reagent



Stimulation with MHC_{CMV1} /aCD28 PAX reagent

Conclusion:

- PAX Stimulation results in proliferation of virus-specific cells
- Proliferation is highly antigen-specific and CD28 dependent
- Similar results obtained w. naïve MART-1 specific cells




Stimulation with MHC _{CMV1} P	PAX reagent (no aCD28)
--	------------------------

	Frequency of HLA-A*0201/MART-1 specific CD8+ T cells out of all CD8+ T cells		
Days of			
culture	D205	D215	D219
0	0,029	0	0,026
13	0,26	2,15	1
33	5,68	8,74	87,4




Antigen specific activation of TCR engineered T-cell with PAX reagent

- PAX reagents used for stimulation of TCR-T-cell product specific for MHC displaying cancer epitope
- Evaluate activation: expression of surface activation markers + cytokine production (Flow cytometry)



Data kindly provided by Collaborator

Antigen-specific activation of TCR-T cell line with PAX reagent



- PAX reagents can stimulate engineered T cells to
 - produce cytokines
 - upregulate activation surface markers (CD69, CD137)
- Activation is Highly MHCp-specific and CD28 co-stimulation dependent


Antigen-specific expansion of TCRt engineered Cells with PAX reagent

PAX reagents can be used to expand and enrich for transfected/transduced T cells

Expansion is MHCp-specific, and the resulting cell product is highly enriched for engineered cells

Enrichment of engineered TCR expressing cells is comparable to what was achieved with peptide-pulsed antigen presenting cells


TCR engineered CD4+ Th cells are also efficiently expanded by PAX



IMMUDEX°

TAKE HOME MESSAGE

- Everything is customizable! Alleles, peptides, barcodes...
- Technical Support throughout your journey from Reagent Design to Data Interpretation
- Gain access to all our expertise pMHC & TCR engineering, Assay Development, Quality Control and more



PRECISION IMMUNE MONITORING

Thank you for your attention and do reach out!

Valérie Bodemeyer, Technical Application Manager <u>customer@immudex.com</u> Mohammad Salem, PhD, Senior Pharma Business & Solution Manager <u>mas@immudex.com</u>

© Copyright Immudex ApS, Denmark, 2023. All rights reserved.